OverviewSuggest Edit

Veracyte is a genomic diagnostics company. It is engaged in the development of molecular tests that leverage innovations in genomic technology and machine learning to enable diagnostic, prognostic, and treatment decisions in diseases such as thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis.

TypePublic
Founded2008
HQSouth San Francisco, CA, US
Websiteveracyte.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Dec 2019)354(+32%)
Revenue (FY, 2019)$120.4 M(+31%)
Share Price (Jan 2021)$53.4 (+6%)
Cybersecurity ratingCMore

Key People/Management at Veracyte

Bonnie H. Anderson

Bonnie H. Anderson

Chairman of the Board and Chief Executive Officer
Keith Kennedy

Keith Kennedy

Chief Operating Officer and Chief Financial Officer
Giulia C. Kennedy

Giulia C. Kennedy

Chief Scientific Officer and Chief Medical Officer
John W. Hanna

John W. Hanna

Chief Commercial Officer
James Erlinger

James Erlinger

Executive Vice President, General Counsel and Secretary
Alfred Bowie

Alfred Bowie

Vice President, Corporate and Business Development
Show more

Veracyte Office Locations

Veracyte has offices in South San Francisco and Austin
South San Francisco, CA, US (HQ)
6000 Shoreline Ct #300
Austin, TX, US
12357 Riata Trace Pkwy #100
Show all (2)

Veracyte Financials and Metrics

Veracyte Revenue

Embed Graph
View revenue for all periods
Veracyte's revenue was reported to be $120.37 m in FY, 2019 which is a 30.8% increase from the previous period.
USD

Revenue (Q3, 2020)

31.1m

Net income (Q3, 2020)

(4.1m)

EBIT (Q3, 2020)

(4.1m)

Market capitalization (19-Jan-2021)

3.1b

Closing stock price (19-Jan-2021)

53.4

Cash (30-Sept-2020)

345.1m

EV

2.8b
Veracyte's current market capitalization is $3.1 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

72.0m92.0m120.4m

Revenue growth, %

28%31%

Cost of goods sold

28.2m33.1m36.5m

Gross profit

43.8m58.9m83.8m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

20.0m22.8m23.5m29.5m30.1m31.0m31.1m20.7m31.1m

Cost of goods sold

7.9m8.2m8.3m8.5m8.8m9.1m12.2m7.7m

Gross profit

12.2m14.5m15.2m21.0m21.4m21.9m18.9m13.0m

Gross profit Margin, %

61%64%65%71%71%71%61%63%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

33.9m78.0m159.3m

Accounts Receivable

12.7m13.2m19.3m

Prepaid Expenses

2.0m2.4m2.2m

Inventories

5.3m3.4m6.8m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

27.2m23.8m77.8m67.8m192.6m195.7m153.1m147.5m345.1m

Accounts Receivable

13.2m13.0m12.3m16.6m19.6m23.6m19.1m15.3m17.6m

Prepaid Expenses

2.1m1.8m1.8m2.4m2.6m2.2m3.0m2.9m3.2m

Inventories

4.6m3.0m3.5m3.8m5.1m6.6m6.1m7.0m4.5m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(31.0m)(23.0m)(12.6m)

Depreciation and Amortization

3.8m3.9m4.1m

Inventories

(1.8m)1.9m(3.4m)

Accounts Payable

1.7m(1.6m)(141.0k)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(9.2m)(15.4m)(19.9m)(1.9m)(4.4m)(5.1m)(11.7m)(22.7m)(26.9m)

Depreciation and Amortization

980.0k2.0m3.0m945.0k1.9m2.8m2.0m3.9m5.9m

Inventories

767.0k2.3m1.9m(366.0k)(1.7m)(3.2m)(376.0k)(1.3m)1.3m

Accounts Payable

(510.0k)(1.9m)(2.6m)1.7m1.7m2.5m5.5m122.0k(534.0k)
USDFY, 2017

EV/EBIT

-8.1 x

EV/CFO

-8.9 x

Revenue/Employee

292.5k

Debt/Equity

0.7 x

Debt/Assets

0.3 x

Financial Leverage

2.1 x

P/E Ratio

(7.2)
Show all financial metrics

Veracyte Operating Metrics

FY, 2017Q1, 2018Q2, 2018Q3, 2018FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020Q2, 2020

Genomic Classifiers Reported

26.03 k6.86 k7.69 k8.01 k31.71 k9.16 k9.66 k9.94 k39.61 k10.56 k5.38 k

Genomic Tests Offered

3 3 5

Completed Clinical Studies to Date

30 38 45

Facilities

2 2 2
Show all operating metrics

Veracyte Acquisitions / Subsidiaries

Company NameDateDeal Size
Allegro DiagnosticsSeptember 04, 2014$21 m
Veracyte International Corp.

Veracyte Revenue Breakdown

Embed Graph

Veracyte revenue breakdown by business segment: 89.2% from Testing Revenue, 6.7% from Biopharmaceutical Revenue and 4.1% from Other

Veracyte Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Veracyte Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Veracyte Online and Social Media Presence

Embed Graph

Veracyte Company Culture

  • CEO Rating

    A+

    100/100

Learn more on Comparably

Veracyte News and Updates

Veracyte to Present at Upcoming Investor Conferences

Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to participate in two upcoming virtual investor conferences

Veracyte Inc (NASDAQ:VCYT) Short Interest Down 23.7% in August

Veracyte Inc (NASDAQ:VCYT) was the recipient of a significant decline in short interest during the month of August. As of August 14th, there was short interest totalling 4,550,000 shares, a decline of 23.7% from the July 30th total of 5,960,000 shares. Based on an average trading volume of 595,500 s…

Veracyte Named a San Francisco Bay Area “Top Workplace” for Seventh Consecutive Year

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that it has been awarded a Top Workplaces 2020 honor by the Bay Area News Group for the seventh consecutive year. The annual award is based solely on employee feedback gathered through an anonymous, third-party sur…

Veracyte Inc. (VCYT) Soars 3.65% on August 13

Veracyte Inc. (VCYT) had a good day on the market for Thursday August 13 as shares jumped 3.65% to close at $33.78. About 668,827 shares traded hands on 7,234 trades for the day, compared with an average daily volume of n/a shares out of a total float of 57.48 million. After opening the trading day …

Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,900,000 shares of common stock, including 900,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $30.00 per share. The net proceeds to Veracyte…

Veracyte Announces Positive Clinical Utility Data for Percepta Classifier Published in CHEST

Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of new data demonstrating that the Percepta® classifier significantly reduces invasive procedures in lung cancer diagnosis by classifying nearly 40 percent of patients as “low risk” when bronchoscopy is inconclusive. The findings, from a …
Show more

Veracyte Blogs

Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference

Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference Content Import Wed, 01/06/2021 - 14:01 Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference Jan 6, 2021 This release is a backfill from a News Wire Gen…

Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer

Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer Content Import Tue, 12/22/2020 - 08:15 Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer Dec 22, 2020 This release is a backfill from a News Wire …

Veracyte Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System

Veracyte Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System Content Import Mon, 12/21/2020 - 08:15 Veracyte Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System Dec 21, 2020 T…

Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests

Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests Content Import Wed, 12/16/2020 - 12:00 Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests Dec 16, 2020 This release is a backfil…

Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson

Collaboration to Focus on 9,000-Patient Clinical Trial for Development of Future Lung Cancer Early-Detection Tests SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 15, 2020-- Veracyte, Inc. (Nasdaq: VCYT) today announced it has expanded its long-term strategic collaboration with the Lung Cancer

Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 3, 2020-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, will host a Virtual Lung Cancer R&D Day for investors and analysts on December 16, 2020 , from 10:00 a.m. to 12:00 p.m. EST .
Show more

Veracyte Frequently Asked Questions

  • When was Veracyte founded?

    Veracyte was founded in 2008.

  • Who are Veracyte key executives?

    Veracyte's key executives are Bonnie H. Anderson, Keith Kennedy and Giulia C. Kennedy.

  • How many employees does Veracyte have?

    Veracyte has 354 employees.

  • What is Veracyte revenue?

    Latest Veracyte annual revenue is $120.4 m.

  • What is Veracyte revenue per employee?

    Latest Veracyte revenue per employee is $340 k.

  • Who are Veracyte competitors?

    Competitors of Veracyte include Biodesix, Roka Bioscience and ID Genomics.

  • Where is Veracyte headquarters?

    Veracyte headquarters is located at 6000 Shoreline Ct #300, South San Francisco.

  • Where are Veracyte offices?

    Veracyte has offices in South San Francisco and Austin.

  • How many offices does Veracyte have?

    Veracyte has 2 offices.